



# Technical Bulletin

## NGS Oncology Tumor Profile Update - ComboMATCH Approved

**TO:** Physicians, Clinical Staff, and Clients

**FROM:** Dr. Christopher Lum, MD,  
Medical Director-Molecular Diagnostics, DLS

Dr. Amy Woron, PhD, MPH,  
V.P. - Technical Director  
Microbiology & Molecular Labs, DLS

Dr. Wesley Kim, MD,  
Medical Director DLS and QMC West

**DATE:** September 8, 2025

**SUBJECT:** DLS NGS Oncology Tumor Profile assay approved by NCI for ComboMATCH eligibility

As of July 24, 2025, DLS joined the prestigious network of over 30 commercial and academic labs participating in the National Cancer Institute's (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) managed by the ECOG-ACRIN Cancer Research Group. ComboMATCH evaluation will now be part of the DLS NGS Oncology Tumor Profile test. All patients who receive this evaluation will allow oncologists or treating physicians to determine patients' eligibility for ComboMATCH trials.

ComboMATCH, funded and sponsored by the NCI, part of the National Institutes of Health, is a group of precision medicine cancer clinical trials, including a registration trial, designed to evaluate the effectiveness of treating cancer with drug combinations targeting specific genetic alterations identified through the DLS NGS Oncology Tumor Profile assay, expanding the treatment options available to patients.

- Multiple treatment trials are available, enrolling patients whose tumors exhibit the targeted genetic profile
- For patients with locally advanced or metastatic solid tumors that have progressed on at least one line of standard therapy, or have no standard treatment that has been shown to prolong survival, this trial offers new hope by testing promising drug combinations tailored to the unique genetic changes in their cancer
- By focusing on each patient's individual tumor profile, ComboMATCH can identify treatments that might control the cancer when traditional treatments are no longer working, or there is no standard treatment, helping doctors explore new treatment options for patients who need them the most
- These drug combinations are either FDA-approved for specific cancers or are currently being studied in other clinical trials, having demonstrated potential effectiveness against tumors with particular genetic changes

When a patient's DLS NGS Oncology Tumor Profile results show alterations targeted by the drug combinations in the ComboMATCH study, the treating physician and enrollment site will work closely to review the test results and clinical data to determine eligibility and enroll the patient. Visit <https://www.ecog-acrin.org/combomatch> to access the Patient Registration Trial information, educational materials, and more.

To submit your patient case for profiling, please order NGS Oncology Tumor Profile (7206).

Order Code	Test Name	Specimen Requirement	CPT
7206	NGS Oncology Tumor Profile	Formalin-Fixed Paraffin-Embedded Tissue (FFPE) block	81479 or 81455

Refer any questions to Jason Pon, Manager, Molecular at (808) 441-5469 or Zan Halford, Technical Coordinator, Molecular at (808) 485-6677

**Diagnostic Laboratory Services, Inc.**  
99-859 Iwaiwa Street – Aiea, HI 96701  
(808) 589-5100 – [www.dlslab.com](http://www.dlslab.com)